Drugs

Category / Pharmaceuticals & Biotech / Drugs

Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on VIBATIV(R) (telavancin) for the Treatment of Nosocomial Pneumonia

Sirona Biochem's Cosmetic Skin Lighteners More Stable Than Leading Compound, According to New Study

VANCOUVER, BRITISH COLUMBIA: Company's Compound Does Not Release Hydroquinone, a Major Concern of Currently Marketed Skin Lighteners ...

Genetic Technologies Provides Update on Board and Management Changes

MELBOURNE, AUSTRALIA: ...

LifeSci Advisors Initiates Coverage of RXi Pharmaceuticals

NEW YORK, NY: RXI-109 Has the Potential to Become the First FDA Approved Product for Scar Prevention and Reduction Available for Download at www.lifesciadvisors.com/clients/rxi/ ...

Xylitol Canada Inc. Financial Results for Three and Nine Months Ended September 30, 2012

TORONTO, ONTARIO: ...

Theravance Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee Meeting on VIBATIV(R) (telavancin)

SOUTH SAN FRANCISCO, CA: ...

Sirona Biochem's Second Skin Lightening Compound Shows Superiority Over Industry Standard in Study

VANCOUVER, BRITISH COLUMBIA: ...

Pfizer Canada Announces New Lower Price for VIAGRA

KIRKLAND, QUEBEC: ...

Sirona Biochem's Subsidiary TFChem Winner of Acclaimed Innovation Award in France

VANCOUVER, BRITISH COLUMBIA: Winners Selected for Patent Strength, Competitive Advantage and Growth Potential ...

Sarepta Therapeutics to Present Company Overview at the 2012 24th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, MA: Webcast Accessible via Sarepta Therapeutics Website ...

Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial

EDEN PRAIRIE, MN and SYDNEY, AUSTRALIA: ...

Biopharm Asia Intends to Reinstate Listing on OTCBB

TONGHUA, CHINA: ...

Sirona Biochem's Skin Lightener Compound Seven Times More Effective Than Popular Commercial Lightener in Study

VANCOUVER, BRITISH COLUMBIA: Compound viability in $9 billion market established; Product development takes next steps ...

Boston Therapeutics' Newly Appointed Chief Operating Officer Invests $625,000 in the Company's S-1 Financial Offering

MANCHESTER, NH: ...

Prima BioMed Releases Interim Immune Monitoring Data From CVac Clinical Trial

SYDNEY, AUSTRALIA: Interim Immune Monitoring Data Demonstrate Positive Effects of CVac(TM); Conference Call to Present the Data Scheduled for November 15th ...

Sirona Biochem Announces Stock Options Exercise Price Revision

VANCOUVER, BRITISH COLUMBIA: ...

NuPathe Announces Third Quarter 2012 Financial Results and Operational Highlights

CONSHOHOCKEN, PA: ...

SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

FOSTER CITY, CA: ...

Medivation Reports Third Quarter Financial Results and Provides Corporate Update

SAN FRANCISCO, CA: $14.1 Million in Net Sales Reflect First 12 Business Days of XTANDI Launch; Conference Call Today at 4:30 p.m. Eastern Time ...

SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook